VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung

R. T. Eagan; E. T. Creagan; J. N. Ingle; J. Rubin; S. Frytak; L. K. Kvols; T. R. Fleming

doi:10.1177/030089167906500112

VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung

R. T. Eagan, E. T. Creagan, J. N. Ingle, J. Rubin, S. Frytak, L. K. Kvols, T. R. Fleming

Medical Oncology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, the authors were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.

Original language	English (US)
Pages (from-to)	105-109
Number of pages	5
Journal	Unknown Journal
Volume	65
Issue number	1
DOIs	https://doi.org/10.1177/030089167906500112
State	Published - 1979

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1177/030089167906500112

Cite this

@article{6e9707a596ed414998342a66f4d589d5,

title = "VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung",

abstract = "In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, the authors were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.",

author = "Eagan, {R. T.} and Creagan, {E. T.} and Ingle, {J. N.} and J. Rubin and S. Frytak and Kvols, {L. K.} and Fleming, {T. R.}",

year = "1979",

doi = "10.1177/030089167906500112",

language = "English (US)",

volume = "65",

pages = "105--109",

journal = "Unknown Journal",

issn = "1931-857X",

publisher = "American Physiological Society",

number = "1",

}

TY - JOUR

T1 - VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung

AU - Eagan, R. T.

AU - Creagan, E. T.

AU - Ingle, J. N.

AU - Rubin, J.

AU - Frytak, S.

AU - Kvols, L. K.

AU - Fleming, T. R.

PY - 1979

Y1 - 1979

N2 - In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, the authors were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.

AB - In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, the authors were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.

UR - http://www.scopus.com/inward/record.url?scp=0018772474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018772474&partnerID=8YFLogxK

U2 - 10.1177/030089167906500112

DO - 10.1177/030089167906500112

M3 - Article

C2 - 442215

AN - SCOPUS:0018772474

SN - 1931-857X

VL - 65

SP - 105

EP - 109

JO - Unknown Journal

JF - Unknown Journal

IS - 1

ER -

VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this